|
| 36176014 | The Impact of COVID-19 Pandemic on Spine Surgeons Worldwide: A One Year Prospective Comparative Study. | Global Spine J | 2024 |
| 37619833 | Reduced Bioactive Microbial Products (Pathogen-Associated Molecular Patterns) Contribute to Dysregulated Immune Responses and Impaired Healing in Infected Wounds in Mice with Diabetes. | J Invest Dermatol | 2024 |
| 36611992 | <i>Pseudomonas aeruginosa</i>: Infections, Animal Modeling, and Therapeutics. | Cells | 2023 |
| 37455214 | Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808. | Clin Genitourin Cancer | 2023 |
| 37187429 | Minimum thresholds deemed acceptable by patients and physicians for sensitivity and specificity of mobile skin cancer screening algorithms. | J Am Acad Dermatol | 2023 |
| 37385724 | Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. | J Immunother Cancer | 2023 |
| 37433716 | Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer. | J Immunother Cancer | 2023 |
| 37333086 | Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target. | Res Sq | 2023 |
| 34284930 | The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy. | Urol Oncol | 2022 |
| 35538548 | Refining colorectal cancer classification and clinical stratification through a single-cell atlas. | Genome Biol | 2022 |
| 35831907 | Correction: Refining colorectal cancer classification and clinical stratification through a single-cell atlas. | Genome Biol | 2022 |
| 35857290 | Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. | JAMA Dermatol | 2022 |
| 35454006 | Gut Microbial Shifts Indicate Melanoma Presence and Bacterial Interactions in a Murine Model. | Diagnostics (Basel) | 2022 |
| 36328377 | FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. | J Immunother Cancer | 2022 |
| 36008193 | First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin. | Eur Urol | 2022 |
| 35314778 | Presence of CrkI-containing microvesicles in squamous cell carcinomas could have ramifications on tumor biology and cancer therapeutics. | Sci Rep | 2022 |
| 35277504 | CrkII/Abl phosphorylation cascade is critical for NLRC4 inflammasome activity and is blocked by Pseudomonas aeruginosa ExoT. | Nat Commun | 2022 |
| 34907595 | Therapeutic evaluation of immunomodulators in reducing surgical wound infection. | FASEB J | 2022 |
| 35050310 | Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. | JAMA Oncol | 2022 |
| 34517005 | IL-10 Dysregulation Underlies Chemokine Insufficiency, Delayed Macrophage Response, and Impaired Healing in Diabetic Wounds. | J Invest Dermatol | 2022 |
| 33132024 | Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy. | Urol Oncol | 2021 |
| 33683074 | Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides. | J Drugs Dermatol | 2021 |
| 33821556 | Pseudomonas aeruginosa ExoT induces G1 cell cycle arrest in melanoma cells. | Cell Microbiol | 2021 |
| 33867192 | A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. | Eur Urol | 2021 |
| 33731690 | Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition. | NPJ Genom Med | 2021 |
| 33507824 | Editorial Comment. | J Urol | 2021 |
| 34018286 | A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation. | Oncologist | 2021 |
| 32881420 | Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. | Cancer Rep (Hoboken) | 2020 |
| 33081107 | Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer. | Int J Mol Sci | 2020 |
| 30511964 | Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression. | J Clin Invest | 2019 |
| 31797796 | Sebaceous carcinoma: evidence-based clinical practice guidelines. | Lancet Oncol | 2019 |
| 31412682 | Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers. | Cancers (Basel) | 2019 |
| 31546879 | Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice. | Cancers (Basel) | 2019 |
| 31199709 | Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. | J Oncol Pract | 2019 |
| 31011407 | The Discovery of Biomarkers in Cancer Immunotherapy. | Comput Struct Biotechnol J | 2019 |
| 30789412 | Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805). | Am J Clin Oncol | 2019 |
| 29275833 | Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8<sup>+</sup> T-cells Derived from Patients with Metastatic Castrate-resistant Disease. | Eur Urol | 2018 |
| 29976296 | The Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (or Onco-Cardiology) and Call to Action. | J Am Coll Cardiol | 2018 |
| 30189123 | Brief spiritual well-being screening is nonlinearly related to psychological distress in ambulatory cancer patients. | Psychooncology | 2018 |
| 31501807 | Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations. | JCO Precis Oncol | 2018 |
| 30373846 | Type 2 Innate Lymphoid Cells Impede IL-33-Mediated Tumor Suppression. | J Immunol | 2018 |
| 30396493 | The relationship between ehrlichiosis and the development of hematologic malignancies. | Med Hypotheses | 2018 |
| 30303516 | NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. | Cancer | 2018 |
| 29559559 | Anaplastic Lymphoma Kinase Mutation (<i>ALK</i> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. | Clin Cancer Res | 2018 |
| 28011934 | Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. | J Immunol | 2017 |
| 28334439 | A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). | Cancer | 2017 |
| 29043290 | Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease? | ACG Case Rep J | 2017 |
| 28600132 | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. | Lancet | 2017 |
| 28624319 | The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review. | Clin Genitourin Cancer | 2017 |
| 26969090 | Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. | Lancet | 2016 |